(Q33359545)

26 July 2017

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection (English)

1 reference

chronic lymphocytic leukemia

26 July 2017

0 references

1 reference

1 reference

1 reference

1 reference

1 reference

Ulrike Heider

1

1 reference

26 July 2017

Claudia Fleissner

2

1 reference

26 July 2017

Ivana Zavrski

3

1 reference

26 July 2017

Christian Jakob

4

1 reference

26 July 2017

Toralf Dietzel

5

1 reference

26 July 2017

Jan Eucker

6

1 reference

26 July 2017

Johann Ockenga

7

1 reference

26 July 2017

Kurt Possinger

8

1 reference

26 July 2017

Orhan Sezer

9

1 reference

26 July 2017

1 January 2004

1 reference

European Journal of Haematology

26 July 2017

1 reference

26 July 2017

72

1 reference

26 July 2017

1

1 reference

26 July 2017

64-66

1 reference

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

26 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

C ASE R EPORT: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2004.00180.X

10.1046/J.0902-4441.2004.00180.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference